Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Now Rated "Hold" by Wall Street Brokerages

Key Points

• Analyst consensus is “Hold”: Of the 10 brokerages covering Bicycle Therapeutics, five recommend buying, three rate it a hold, and two recommend selling. The average 12-month price target is $13.86.
• Shares remain near their 12-month low: BCYC opened at $3.57, compared with a 12-month range of $3.33 to $9.08, while institutional investors own 86.15% of the company.
• Latest results missed expectations: Bicycle Therapeutics reported a quarterly loss of $0.72 per share versus the expected $0.58 loss and revenue of $0.63 million versus the $4.22 million consensus estimate.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $13.86.

A number of brokerages have recently commented on BCYC. Wall Street Zen upgraded Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Zacks Research downgraded shares of Bicycle Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday, October 14th. Weiss Ratings restated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Finally, Needham & Company LLC dropped their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BCYC. Renaissance Technologies LLC lifted its stake in shares of Bicycle Therapeutics by 72.8% in the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company's stock valued at $4,544,000 after buying an additional 412,700 shares during the period. Rangeley Capital LLC increased its stake in Bicycle Therapeutics by 76.0% during the first quarter. Rangeley Capital LLC now owns 232,260 shares of the company's stock valued at $1,078,000 after acquiring an additional 100,260 shares during the period. Marquette Asset Management LLC bought a new position in Bicycle Therapeutics during the second quarter valued at about $309,000. ADAR1 Capital Management LLC bought a new position in Bicycle Therapeutics during the first quarter valued at about $331,000. Finally, Principal Financial Group Inc. raised its holdings in Bicycle Therapeutics by 2.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company's stock valued at $5,450,000 after acquiring an additional 26,353 shares in the last quarter. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $3.57 on Thursday. Bicycle Therapeutics has a twelve month low of $3.33 and a twelve month high of $9.08. The stock has a market capitalization of $249.86 million, a PE ratio of -1.31 and a beta of 1.68. The stock has a 50-day simple moving average of $3.89 and a 200 day simple moving average of $4.23.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The business had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. As a group, equities research analysts forecast that Bicycle Therapeutics will post -2.26 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc NASDAQ: BCYC is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.